Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirr

StephenW

<http://www.cghjournal.org/article/PIIS1542356510012279/abstract?rss=yes>

Clinical Gastroenterology and Hepatology
Volume 9, Issue 3 , Pages 274-276.e1, March 2011

Schiff ER et al. - Chronic hepatitis B patients with advanced fibrosis or
cirrhosis demonstrated histologic improvement and reversal of fibrosis and
cirrhosis after long-term treatment with entecavir.

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or
Cirrhosis in Patients With Chronic Hepatitis B

Affiliations
University of Miami Hospital and Clinics, Miami, Florida
Reprint requests Address requests for reprints to: Eugene R. Schiff, MD, Center
for Liver Diseases, University of Miami, 1500 NW 12th Avenue, Suite 1011, East
Tower, Miami, Florida 33136; fax: (305) 243–3877

Background & Aims
Long-term treatment with entecavir resulted in durable virologic suppression and
continued histologic improvement in nucleoside-naive chronic hepatitis B
patients. Patients with advanced fibrosis or cirrhosis, who received long-term
entecavir treatment, were evaluated for improvement in liver histology.

Methods
The study included a subset of patients from phase III and long-term rollover
studies, who received entecavir for at least 3 years, had advanced fibrosis or
cirrhosis, and evaluable biopsies at baseline and after long-term treatment.

Results
Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis
score, ≥4). After approximately 6 years of cumulative entecavir therapy
(range, 267–297 wk), all 10 patients showed improvement in liver histology and
Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and
Knodell necroinflammatory scores were −2.2 and −7.6, respectively. A
reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients
who had cirrhosis at baseline.

Conclusions
Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated
histologic improvement and reversal of fibrosis and cirrhosis after long-term
treatment with entecavir.



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

临床胃肠病学和肝病学
第9卷，第3期，页274 276.e1，2011年3月

希夫急诊室等。 - 慢性乙型肝炎患者的肝纤维化或先进
肝硬化的病理表现出改善和逆转肝纤维化和
肝硬化经过长期恩替卡韦治疗。

长期与恩替卡韦治疗晚期肝纤维化逆转诱导或
在慢性肝炎肝硬化患者乙

兼职
迈阿密大学医院和诊所，迈阿密，佛罗里达州
再版重印请求，请求地址为：尤金河希夫医师，中心
肝脏疾病，迈阿密大学，西北第十二大街1500，1011室，东
塔，迈阿密，佛罗里达州33136，传真：（305）243-3877

背景和目的
长期与恩替卡韦治疗导致持久的病毒学抑制和
在核苷初治慢性肝炎组织学持续改善乙
病人。例晚期肝纤维化或肝硬化，谁获得长期
恩替卡韦治疗，进行了评价肝组织学改善。

方法
该研究的病患，包括从第三阶段和长期过渡的一个子集
研究中，谁收到了至少3年恩替卡韦，已经晚期肝纤维化或
肝硬化和评估的活组织切片检查后，在基线和长期治疗。

结果
十的患者在基线（Ishak纤维化或肝硬化晚期肝纤维化
评分，≥4）。经过大约6年来累计恩替卡韦治疗
（范围267-297周），所有10例肝组织学显示，改善和
Ishak纤维化评分。从基线的平均变化中，Ishak纤维化
Knodell坏死性炎症评分为-2.2和-7.6，分别为。一
Ishak纤维化评分减少到4个或更少有人对所有4例
谁曾在基线肝硬化。

结论
慢性乙型肝炎肝纤维化或肝硬化晚期患者表现
组织学改善和逆转肝纤维化和肝硬化经过长期
恩替卡韦治疗。

StephenW

经过大约6年累计恩替卡韦
治疗（范围267-297周），所有10个病患在肝脏改善
组织学和Ishak纤维化评分。
<http://www.cghjournal.org/article/PIIS1542356510012279/abstract?rss=yes>

Clinical Gastroenterology and Hepatology
Volume 9, Issue 3 , Pages 274-276.e1, March 2011.

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or
Cirrhosis in Patients With Chronic Hepatitis B

Eugene R. Schiff, et al.

published online 10 December 2010.

Abstract

Background & Aims
Long-term treatment with entecavir resulted in durable virologic suppression and
continued histologic improvement in nucleoside-naive chronic hepatitis B
patients. Patients with advanced fibrosis or cirrhosis, who received long-term
entecavir treatment, were evaluated for improvement in liver histology. Methods
The study included a subset of patients from phase III and long-term rollover
studies, who received entecavir for at least 3 years, had advanced fibrosis or
cirrhosis, and evaluable biopsies at baseline and after long-term treatment.
Results Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak
fibrosis score, ≥4). After approximately 6 years of cumulative entecavir
therapy (range, 267–297 wk), all 10 patients showed improvement in liver
histology and Ishak fibrosis score. The mean change from baseline in Ishak
fibrosis and Knodell necroinflammatory scores were −2.2 and −7.6,
respectively. A reduction in Ishak fibrosis score to 4 or less was observed for
all 4 patients who had cirrhosis at baseline. Conclusions Chronic hepatitis B
patients with advanced fibrosis or cirrhosis demonstrated histologic improvement
and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.

StephenW

临床胃肠病学和肝病学
第9卷，第3期，页274 276.e1，2011年3月。

长期与恩替卡韦治疗晚期肝纤维化逆转诱导或
在慢性肝炎肝硬化患者乙

尤金河希夫，等。

线上发表二〇一〇年十二月十日。

摘要

背景和目的
长期与恩替卡韦治疗导致持久的病毒学抑制和
在核苷初治慢性肝炎组织学持续改善乙
病人。例晚期肝纤维化或肝硬化，谁获得长期
恩替卡韦治疗，进行了评价肝组织学改善。方法
该研究的病患，包括从第三阶段和长期过渡的一个子集
研究中，谁收到了至少3年恩替卡韦，已经晚期肝纤维化或
肝硬化和评估的活组织切片检查后，在基线和长期治疗。
结果10例患者在基线晚期肝纤维化或肝硬化（伊沙克
纤维化评分，≥4）。经过大约6年累计恩替卡韦
治疗（范围267-297周），所有10个病患在肝脏改善
组织学和Ishak纤维化评分。从基线的平均变化中，Ishak
Knodell坏死性炎症和纤维化评分-2.2和-7.6，
分别。以Ishak纤维化评分降低到4个或更少的观察
所有4例谁在基线肝硬化。结论慢性乙型肝炎
晚期纤维化或肝硬化病人表现出组织学改善
和纤维化，后长期使用恩替卡韦治疗肝硬化的逆转。